摘要
目的探讨重组人血管内皮抑素联合mFOLFOX4化疗方案治疗晚期原发性肝癌的临床疗效及安全性。方法选择晚期原发性肝癌患者84例作为研究对象,将其按照就诊顺序编号随机分为对照组与观察组,每组42例。对照组采用以mFOLFOX4为主的化疗综合治疗方案,观察组在对照组治疗基础上,再予以重组人血管内皮抑素治疗。2组患者均行4个周期治疗。比较2组患者治疗前、完成治疗后一周内、6个月、3年目标肿瘤的直径,评价2组患者治疗后的近、远期疗效。收集患者治疗过程中的不良反应并比较。比较2组患者1年期、2年期、3年期生存率。结果完成治疗后6个月、3年对照组患者临床总有效率分别为35.71%、4.76%、,观察组分别为47.62%、9.52%;观察组近远期临床疗效均明显高于对照组(P<0.05);对照组3年随访期内死亡率83.33%,观察组为69.05%,观察组3年死亡率明显低于对照组(P<0.05)。治疗期间2组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人血管内皮抑素联合mFOLFOX4化疗方案治疗晚期原发性肝癌可明显提高临床疗效,提高患者的3年生存率,且不增加患者的不良反应,对晚期原发性肝癌患者具有较高的临床价值。
Objective To observe the clinical efficacy and safety of recombinant human endostatin combined with mFOLFOX4 chemotherapy in the treatment of advanced primary liver cancer. Methods 84 cases of patients with advanced primary liver cancer were selected as the research object,and were randomly divided into the control group and the observation group,each with 42 cases.The control group was treated with mFOLFOX4 based chemotherapy,while the observation group was treated with recombinant human endostatin orally on the basis of the control group.Both groups of patients were treated with 4 cycles.The 2 groups of patients before and after the completion of treatment within 1 week,6 months,3 years,the diameter of the target tumor were compared,The short-and long-term efficacy of the 2 groups of patients after treatment were analyzed.The side effects of the treatment were collected and compared.1-year/2-year/3-year survival rates were compared. Results 6 months and 3 years after completion of therapy,clinical total effective rate in the control group were 35.71%,4.76%,and the observation group were 47.62% and 9.52%;the observation group short-term and long-term clinical efficacy were significantly higher than the control group（ P 〈0.05）;the control group 3-year mortality rate was 83.33%,and 69.05% in the observation group,3-year mortality rate of the observation group was significantly lower than the control group（ P 〈0.05）;during the treatment,adverse reaction rate of the 2 groups had no significant difference（ P 〉0.05）. Conclusion Recombinant human endostatin combined with mFOLFOX4 chemotherapy in the treatment of advanced primary liver cancer patients can significantly improve the clinical curative effect of the patients,improve the patient＇s 3-year survival rate,without increase the adverse reactions of patients.It has a high clinical value for advanced primary liver cancer.
作者
薛李
田宏
王丽霞
XUE Li;TIAN Hong;WANG Lixia(The Third People＇s Hospital of Panzhihua,Panzhihua,617000)
出处
《实用癌症杂志》
2018年第7期1205-1208,共4页
The Practical Journal of Cancer
